Kyverna therapeutics to attend the 2024 american academy of neurology (aan) annual meeting in denver, co, with data on kyv-101 in the treatment of patients with neurological autoimmune diseases

Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and lambert-eaton myasthenic syndrome with autologous cd19-targeted car-t cells kyverna to host a conference call on april 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis emeryville, calif. , april 11, 2024 /prnewswire/ -- kyverna therapeutics, inc. (nasdaq: kytx), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the american academy of neurology to be held in denver, colorado, starting on april 13.
KYTX Ratings Summary
KYTX Quant Ranking